MetaCap

Janux Therapeutics (JANX) vs Lexicon Pharmaceuticals (LXRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lexicon Pharmaceuticals (LXRX) has outperformed Janux Therapeutics (JANX) over the past year, gaining 14.2% versus a loss of 65.0%. Over five years, JANX leads with a -42.9% price change compared with -67.7% for LXRX. Lexicon Pharmaceuticals is the larger company by market cap ($681.2 million vs $616.7 million), about 1.1 times the size.

Lexicon Pharmaceuticals converts more of its revenue into profit, with a net margin of -101.1% versus -1136.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

JANX-65.00%LXRX+14.18%
+105%+16%-73%
Nov 21, 20251 yearNov 20, 2026
JANX-43.62%LXRX-69.15%
+281%+85%-111%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

JANX versus LXRX key metrics
MetricJANXLXRX
Share price$10.08$1.53
Market cap$616.73M$681.21M
1-day change-2.04%-8.38%
YTD return-26.96%+33.04%
1-year return-65.00%+14.18%
5-year return-42.92%-67.72%
EPS (TTM)$-1.59$-0.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$10.00M$49.80M
Revenue growth (YoY)-5.55%+60.24%
Net income (latest FY)$-113.63M$-50.34M
Gross margin—99.45%
Operating margin-1576.67%-98.21%
Net margin-1136.25%-101.08%
52-week high$35.34$2.68
52-week low$10.05$1.10
Distance from 52-week high-71.48%-42.91%
Analyst consensusstrong_buybuy
Avg. price target upside+228.77%+195.42%
Average volume961.56K2.56M
Shares outstanding61.18M445.23M
Employees11481
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LXRX has outperformed JANX by 79.2 percentage points over the past year.
  • Lexicon Pharmaceuticals is more profitable, keeping -101.1 cents of every revenue dollar as net income versus -1136.3 cents for Janux Therapeutics.
  • Lexicon Pharmaceuticals grew revenue faster in its latest fiscal year (+60.24% vs -5.55%).

About Janux Therapeutics

JANX stock →

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 114 employees

About Lexicon Pharmaceuticals

LXRX stock →

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.

Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees

JANX vs LXRX FAQ

Which is bigger, Janux Therapeutics or Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (LXRX) is larger, with a market capitalization of $681.21M compared with $616.73M for Janux Therapeutics (JANX).

Which stock has performed better over the past year, JANX or LXRX?

LXRX returned +14.18% over the past 12 months, compared with -65.00% for JANX (price return, excluding dividends). Past performance does not predict future results.

Are Janux Therapeutics and Lexicon Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons